OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment.
Glioblastoma (GBM) is an incurable disease ranked among the deadliest solid cancers worldwide. A better understanding on the molecular aspects of this malignancy could contribute to the development of new treatment strategies and help to improve survival rates. Previously, our group had shown that GBM patients expressing the cancer/testis antigen Opa Interacting Protein 5 (OIP5) present a longer survival period than the OIP5-negative group. The main goal of this study was to evaluate the OIP5 contribution to GBM tumorigenesis and assess the role of OIP5 in GBM cell response to lomustine, an alkylating agent used in the treatment of this malignancy. So, the effect of OIP5 knockdown was evaluated in A172 and T98G GBM cell lines. Our results demonstrated that downregulation of the OIP5 stimulates glioma cell viability and inhibits cell death-induced necrosis prompted by lomustine. In conclusion, our data shows that OIP5 expression in GBM cells seems to be able to enhance lomustine cytotoxic effects, reinforcing that this gene is a potential therapeutic target and putative molecular biomarker for treatment response in GBM.
['Rodrigues-Junior|Dorival Mendes|DM|', 'Biassi|Thaís Priscila|TP|', 'Carlin|Viviane|V|', 'Buri|Marcus Vinicius|MV|', 'Torrecilhas|Ana Claudia|AC|', 'Bortoluci|Karina Ramalho|KR|', 'Vettore|André Luiz|AL|']
D018906:Antineoplastic Agents, Alkylating D001932:Brain Neoplasms D018797:Cell Cycle Proteins D045744:Cell Line, Tumor D002868:Chromosomal Proteins, Non-Histone D019008:Drug Resistance, Neoplasm D005909:Glioblastoma D006801:Humans D008130:Lomustine
OIP5 Glioblastoma Lomustine Drug resistance